Parkinson’s treatment is evolving on several fronts at once, from new drug delivery methods and smarter brain stimulation to the first human trials of stem cell transplants and a diagnostic test that can detect the disease years before symptoms appear. While no therapy yet slows the underlying nerve damage, the options for managing symptoms and the tools for earlier, more precise diagnosis have expanded significantly in the past two years.
Generic Drugs Are Lowering Costs
The FDA approved the first generic versions of two important Parkinson’s medications in 2024. Generic pimavanserin, which treats hallucinations and delusions associated with Parkinson’s psychosis, was approved in January 2024 from multiple manufacturers. Generic extended-release amantadine capsules, used to treat dyskinesia (the involuntary movements that develop as a side effect of long-term levodopa use), followed in August 2024. Both had been available only as expensive brand-name drugs, so generic competition should make them more accessible.
Continuous Drug Delivery Under the Skin
One of the biggest practical problems in Parkinson’s is that oral levodopa, the gold-standard medication, wears off between doses. Many people spend 2.5 hours or more each day in an “off” state where their medication isn’t working and movement becomes difficult. A subcutaneous infusion system called ND0612 aims to solve this by delivering a steady stream of levodopa and carbidopa through a small pump worn on the body.
A phase 3 trial (BouNDless) tested the system in people who experienced significant daily off time. The pump delivered medication continuously, smoothing out the peaks and valleys of oral dosing. The primary goal was increasing daily “on” time without troublesome involuntary movements. The most common side effect was skin reactions at the infusion site, which affected 83% of participants during the open-label phase. This is a recurring challenge with any device that sits under the skin for extended periods, and it will likely determine how widely the technology gets adopted.
A Blood-Free Test for Earlier Diagnosis
A laboratory technique called the seed amplification assay can now detect misfolded alpha-synuclein, the protein that clumps inside brain cells in Parkinson’s disease. This test works on spinal fluid and has shown sensitivity between 82% and 100% and specificity between 88% and 100% for people with established Parkinson’s, depending on the study.
The more exciting application is catching the disease earlier. In people with REM sleep behavior disorder, a condition that often precedes Parkinson’s by years, the assay picks up abnormal protein in up to 93% of cases. In people with significant loss of smell (another early warning sign), positivity rates range from 55% to 70% depending on severity, rising to 98.6% in those with both a Parkinson’s diagnosis and typical smell loss. The test’s accuracy drops in the earliest, most ambiguous stages of disease, but it represents the closest thing to an objective Parkinson’s biomarker that exists today. As it becomes more widely available, it could reshape how and when treatment begins.
The GLP-1 Drug Disappointment
Drugs originally developed for type 2 diabetes, called GLP-1 receptor agonists, generated enormous excitement after smaller trials suggested they might actually slow Parkinson’s progression. An early open-label study of exenatide showed a 4.9-point improvement on a standard motor scale compared to controls, and a subsequent double-blind trial showed a 3.5-point advantage that persisted even after the drug was stopped.
But the largest and longest trial to date, published in The Lancet, found no benefit. The 96-week study randomized 194 people with moderate Parkinson’s to weekly exenatide injections or placebo. Motor scores worsened by 5.7 points in the exenatide group and 4.5 points in the placebo group, a difference that was not statistically significant. There was no advantage in younger participants either. The drug was safe and well tolerated, and it did produce measurable changes in brain insulin signaling pathways, but those biological effects didn’t translate into clinical improvement. A similar drug, lixisenatide, showed promise in a shorter one-year phase 2 trial, so the class isn’t completely ruled out, but the exenatide results were a significant setback for the neuroprotection field.
Gene-Targeted Treatments in Early Testing
About 3% to 5% of Parkinson’s cases are linked to specific genetic mutations, and two genes are getting the most therapeutic attention: LRRK2 and GBA1.
LRRK2 mutations cause the overactivity of an enzyme that damages brain cells. Several companies are developing small molecules that block this enzyme’s activity, and these inhibitors are currently in early-phase clinical trials. A separate approach uses antisense oligonucleotides, synthetic molecules that reduce the amount of LRRK2 protein the body produces. Both strategies are still being evaluated for safety and dosing, so efficacy data is likely years away.
GBA1 mutations reduce levels of a housekeeping enzyme in brain cells, leading to a buildup of fatty substances that trigger inflammation and accelerate neurodegeneration. People with GBA1 mutations tend to develop Parkinson’s earlier and progress to cognitive problems faster. A gene therapy called PR001 uses a viral vector to deliver a working copy of the GBA1 gene directly to the brain. Mouse studies showed that restoring normal enzyme activity reduced disease markers, and the therapy is now being tested in Parkinson’s patients carrying GBA1 mutations. If successful, it would be one of the first treatments tailored to a patient’s specific genetic cause of Parkinson’s.
Stem Cell Transplants Show Early Signs of Life
A phase 1/2 trial in Japan transplanted dopamine-producing cells derived from induced pluripotent stem cells (iPSCs) into the brains of seven people with Parkinson’s. Three received a lower dose (about 2.1 to 2.6 million cells per hemisphere) and four received a higher dose (about 5.3 to 5.5 million cells per hemisphere). Published in Nature, the results showed the transplanted cells survived, produced dopamine, and did not form tumors.
Brain imaging confirmed a 44.7% increase in dopamine activity in the target region, with greater increases in the high-dose group. Clinical results were more mixed. Some patients saw their motor symptoms stabilize, while two patients with faster-progressing disease continued to decline, likely because neurodegeneration in non-dopamine systems outpaced the benefit of new dopamine cells. The researchers noted that patients had very high expectations, and subjective experiences didn’t always match the objective imaging improvements. This trial was primarily about proving safety, and on that front it succeeded. Larger trials will be needed to determine whether the dopamine boost translates into meaningful daily improvements.
Smarter Deep Brain Stimulation
Traditional deep brain stimulation (DBS) delivers a constant electrical signal to brain areas involved in movement. It works well but has trade-offs: finding the right stimulation level means balancing symptom relief against side effects like speech difficulty, and the battery drains steadily regardless of what the patient needs moment to moment.
Adaptive DBS (aDBS) uses built-in sensors to read brain signals in real time and adjust stimulation automatically. A recent study found that switching patients from conventional to adaptive DBS produced significant improvements in motor function during off-medication periods. Scores on a standard motor assessment improved, particularly for “wearing off” symptoms, those frustrating periods when medication effects fade before the next dose kicks in. During on-medication periods, scores stayed the same, suggesting that adaptive DBS fills in the gaps that medication alone can’t cover. Younger patients and those with persistent wearing-off symptoms appeared to benefit the most.
Focused Ultrasound Expands Its Reach
MRI-guided focused ultrasound uses hundreds of ultrasound beams converging on a precise brain target to create a tiny, controlled lesion without any incision. The FDA initially cleared it for tremor-dominant Parkinson’s, then expanded approval in 2021 to include additional motor symptoms like rigidity, slowness of movement, and dyskinesia.
The newest FDA clearance adds a target called the pallidothalamic tract, a fiber bundle connecting two movement-control centers in the brain. This approval also permits staged bilateral treatment, meaning the second side of the brain can be treated six months after the first. Previous focused ultrasound approvals were limited to one side, since treating both simultaneously carries higher risks. The staged bilateral option is a meaningful expansion for people with symptoms on both sides of the body. In the U.S., however, Medicare currently covers focused ultrasound only for tremor, so patients with other motor symptoms may face insurance barriers depending on their treatment center.
Wearable Monitors for Better Daily Management
A growing number of wearable devices can now track Parkinson’s symptoms continuously, giving doctors objective data instead of relying solely on what patients recall during a brief office visit. The UK’s National Institute for Health and Care Excellence (NICE) conditionally recommends several of these devices, including PKG (a wrist-worn logger that tracks bradykinesia, dyskinesia, tremor, and on/off fluctuations), Kinesia 360 (which adds mobility and posture tracking), PDMonitor (a multi-sensor system that also detects freezing of gait), and STAT-ON (a waist-worn sensor for gait analysis and fall detection).
Apple Watch-based apps are entering the space as well. StrivePD and Parky claim to detect tremor and dyskinesia, while NeuroRPM adds bradykinesia monitoring with simple yes/no outputs. The practical value of all these devices is in medication timing. If a wearable shows that your off periods cluster in the late afternoon, your neurologist can adjust your dosing schedule based on days or weeks of real data rather than a snapshot from one appointment. Wrist-worn devices tend to be best at picking up tremor, waist-worn sensors are better for detecting dyskinesia and gait problems, and multi-sensor systems that combine both locations offer the most complete picture.